Bluebird Bio Inc (BLUE) 136.49 $BLUE
Is Legalized Marijuana or Gene Therapy the Better Emerging Industry?
George Budwell, The Motley Fool - Motley Fool - Wed Apr 22, 7:59AM CDT
The ability to spot powerful new technologies or industries early on can result in eye-popping returns for investors. The brave few that initially recognized the potential of Tesla Motors ' electric car, for example, have been richly rewarded over...
BLUE: 136.49 (+1.22), TSLA: 219.44 (+10.03), QURE: 26.15 (-1.44), GWPH: 113.04 (-0.05), CLDN: 13.59 (-2.77)
Biotech Stock Mailbag: Bluebird's Sickle Cell Data, Ariad's Faux Suitors, XBiotech Blech
at The Street - Fri Apr 17, 4:59AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
BLUE: 136.49 (+1.22), XBIT: 27.55 (+0.18), ARIA: 9.23 (-0.04)
Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert
Life Sciences Report - Seeking Alpha - Thu Apr 09, 4:59PM CDT
It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised...
PSTI: 2.80 (-0.03), NBS: 2.88 (+0.06), OSIR: 16.35 (-0.10), BCLI: 4.29 (-0.09), MDVN: 128.88 (+0.29), INO: 10.38 (-0.10), CYTX: 0.96 (-0.09), STEM: 0.82 (-0.06), JUNO: 55.72 (-0.68), ATHX: 1.34 (+0.01), CUR: 1.96 (-0.04), BLUE: 136.49 (+1.22), VRTX: 132.85 (+0.65), AMGN: 169.10 (+0.64), KERX: 11.52 (-0.15), OMER: 24.41 (-0.15), KITE: 57.56 (-1.43), GILD: 104.18 (-1.02), MRK: 57.69 (+0.03), TEVA: 63.01 (-1.15)
UniQure Deal Confirms Red-Hot Interest In Advanced Therapies
EP Vantage - at Seeking Alpha - Tue Apr 07, 3:42PM CDT
If there is any sign that pharma is beating the bushes to flush out promising advanced therapies, it is that Bristol-Myers Squibb (NYSE: BMY ) has shelled out $50m to license a preclinical gene therapy project that UniQure (NASDAQ: QURE ) ...
BLUE: 136.49 (+1.22), CLDN: 13.59 (-2.77), BMY: 66.60 (-0.21)
Another IPO Filed In Hot Cancer Immunotherapy Field
at Investor's Business Daily - Tue Apr 07, 12:55PM CDT
Adaptimmune Therapeutics has filed for an initial public offering, adding another company to one of the hottest sectors in the biotech field. U.K.-based Adaptimmune Therapeutics plans to raise up to $150 million and list on the Nasdaq under the...
BLUE: 136.49 (+1.22), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), AMGN: 169.10 (+0.64), JUNO: 55.72 (-0.68)
Why uniQure N.V. Stock Skyrocketed Today
George Budwell, The Motley Fool - Motley Fool - Mon Apr 06, 9:35AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of the Dutch gene-therapy company uniQure ...
BLUE: 136.49 (+1.22), JNJ: 100.43 (+0.13), QURE: 26.15 (-1.44), PFE: 34.93 (+0.04), CLDN: 13.59 (-2.77), BMY: 66.60 (-0.21), NVS: 103.45 (-0.62)
3 Events That Could Sink the Biotech Sector This Year
Brian Orelli, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Sun Apr 05, 8:06AM CDT
The biotech sector has been hot over the last few years, which naturally leads to talk of a biotech bubble. We asked our healthcare experts for potential events that might pop that bubble -- or at least let a little air out. While we're certainly...
BLUE: 136.49 (+1.22), IMS: 27.73 (+0.04), ESRX: 86.12 (+0.02), GILD: 104.18 (-1.02), CLDN: 13.59 (-2.77), ABBV: 64.52 (+0.91)
Celladon: The Next Breakthrough In Cardiovascular Gene Therapy?
DoconStocks - at Seeking Alpha - Tue Mar 31, 7:48AM CDT
BLUE: 136.49 (+1.22), ONCE: 64.79 (-0.25), CLDN: 13.59 (-2.77)
Intrexon and Merck Serono team up in cancer immunotherapy
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 8:05AM CDT
BLUE: 136.49 (+1.22), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), XON: 44.53 (+0.36), JUNO: 55.72 (-0.68)
Today's Review on Biotech Equities -- Biocept, Biogen Idec, Kite Pharma, Organovo Holdings, and Bluebird Bio
PR Newswire - Mon Mar 30, 7:55AM CDT
Editor Note: For more information about this release, please scroll to bottom.
BLUE: 136.49 (+1.22), BIIB: 423.57 (+1.46), KITE: 57.56 (-1.43), ONVO: 5.14 (+0.67), BIOC: 3.15 (+0.02)
1 Clinical-Stage Biotech Stock That Could Make You Into a Millionaire
George Budwell, The Motley Fool - Motley Fool - Sun Mar 29, 7:06AM CDT
Biotech stocks have the ability to absolutely crush it in short order, turning even small investments into respectable sums of money. Investors that caught lightning in a bottle with Acadia Pharmaceuticals prior to the company releasing pivotal...
BLUE: 136.49 (+1.22), ACAD: 38.55 (-0.20), CLDN: 13.59 (-2.77)
Could These Experimental Drugs Eclipse Harvoni's Historic Launch?
Keith Speights, Brian Orelli, and Todd Campbell, The Motley Fool - Motley Fool - Sat Mar 28, 7:02AM CDT
Relatively few drugs attain the esteemed blockbuster status of $1 billion in annual sales. For those that do, many of them take several years to reach that mark. Gilead Sciences , however, raised the bar with the launch of hepatitis C drug Harvoni....
BLUE: 136.49 (+1.22), BIIB: 423.57 (+1.46), ESRX: 86.12 (+0.02), GILD: 104.18 (-1.02), PFE: 34.93 (+0.04), AMGN: 169.10 (+0.64)
Celladon Heart-Failure Study Looms Large as Next Big Test for Gene Therapy
at The Street - Wed Mar 25, 9:06AM CDT
In April, Celladon is expecting results from a mid-stage study of a gene therapy aiming to improve the pumping ability of the heart in patients with advanced heart failure.
BLUE: 136.49 (+1.22), ONCE: 64.79 (-0.25), CLDN: 13.59 (-2.77)
Mast Therapeutics: Investment Opportunity As Phase III Ongoing
Capital Screen - at Seeking Alpha - Fri Mar 20, 10:17AM CDT
BLUE: 136.49 (+1.22), MSTX: 0.50 (+0.01), GLYC: 8.84 (-0.04)
How ARM's Edward Lanphier Is Fighting For Cell Therapy Cures That Save Patients And Portfolios
Life Sciences Report - Seeking Alpha - Fri Mar 20, 6:52AM CDT
Stem cell, gene therapy and genetically modified cell therapy companies have begun to attract serious capital from investors who understand biotechnology and have the wherewithal to move products into the clinic and into the market. But battles still...
BLUE: 136.49 (+1.22), QURE: 26.15 (-1.44), SGMO: 14.37 (-0.03), JUNO: 55.72 (-0.68), ATHX: 1.34 (+0.01), NVS: 103.45 (-0.62)
Juno Therapeutics Comments On Cancer Cure Lifts Group
at Investor's Business Daily - Thu Mar 19, 1:36PM CDT
Enthusiasm about potential cancer cures sent shares of Juno Therapeutics (JUNO) and its peers flying Thursday, though Juno's fourth-quarter earnings late Wednesday missed Wall Street estimates by a lot. "Within the next 12 months, we expect to have...
BLUE: 136.49 (+1.22), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), AMGN: 169.10 (+0.64), JUNO: 55.72 (-0.68), NVS: 103.45 (-0.62)
CAR-T cancer therapy stocks head north
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 12:29PM CDT
BLUE: 136.49 (+1.22), ZIOP: 10.88 (+0.03), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), CNDO: 4.09 (-0.09), CLLS: 31.30 (-0.91), JUNO: 55.72 (-0.68)
CJS Global Complete Janitorial Solutions Expands Services to Central Florida, Signing on Many High-Profile Companies
PR Newswire - Thu Mar 19, 7:45AM CDT
CJS (Complete Janitorial Solutions) Global, founded by successful business owner Taylor Smith in Fort Lauderdale in March 2012, has recently expanded its services to the Orlando market. CJS is pleased to now provide services for renowned franchises in the Orlando, Tampa, Sarasota, Fort Myers, Daytona and Jacksonville areas, including Seasons 52, Dewey's Indoor Golf & Sports Grill, Roy's Hawaiian, Miller's Ale House Restaurant, Blue Martini, Kings Bowling Orlando, Taverna Opa, BRIO Tuscan Grille, Chili's and Bahama Breeze.
BLUE: 136.49 (+1.22)
Cellectis on deck for what should be a very strong IPO
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 9:42AM CDT
BLUE: 136.49 (+1.22), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), PFE: 34.93 (+0.04), CLLS: 31.30 (-0.91), JUNO: 55.72 (-0.68)
bluebird bio to Present at Alliance for Regenerative Medicine's 3rd Annual Regen Med Investor Day
Business Wire - Wed Mar 18, 6:00AM CDT
bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the Alliance for Regenerative Medicine's 3rd Annual Regen Med Investor Day on Wednesday, March 25, 2015 at 4:20 p.m. ET at the Metropolitan Club in New York City. bluebird bio will also participate in a panel titled, "Adoptive T-Cell Therapies: Considering Key Upcoming Clinical & Commercial Milestones" at 3:10 p.m. ET.
BLUE: 136.49 (+1.22)
Is Legalized Marijuana or Gene Therapy the Better Emerging Industry?
George Budwell, The Motley Fool - Motley Fool - Wed Apr 22, 7:59AM CDT
The ability to spot powerful new technologies or industries early on can result in eye-popping returns for investors. The brave few that initially recognized the potential of Tesla Motors ' electric car, for example, have been richly rewarded over...
BLUE: 136.49 (+1.22), TSLA: 219.44 (+10.03), QURE: 26.15 (-1.44), GWPH: 113.04 (-0.05), CLDN: 13.59 (-2.77)
Biotech Stock Mailbag: Bluebird's Sickle Cell Data, Ariad's Faux Suitors, XBiotech Blech
at The Street - Fri Apr 17, 4:59AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
BLUE: 136.49 (+1.22), XBIT: 27.55 (+0.18), ARIA: 9.23 (-0.04)
Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert
Life Sciences Report - Seeking Alpha - Thu Apr 09, 4:59PM CDT
It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised...
PSTI: 2.80 (-0.03), NBS: 2.88 (+0.06), OSIR: 16.35 (-0.10), BCLI: 4.29 (-0.09), MDVN: 128.88 (+0.29), INO: 10.38 (-0.10), CYTX: 0.96 (-0.09), STEM: 0.82 (-0.06), JUNO: 55.72 (-0.68), ATHX: 1.34 (+0.01), CUR: 1.96 (-0.04), BLUE: 136.49 (+1.22), VRTX: 132.85 (+0.65), AMGN: 169.10 (+0.64), KERX: 11.52 (-0.15), OMER: 24.41 (-0.15), KITE: 57.56 (-1.43), GILD: 104.18 (-1.02), MRK: 57.69 (+0.03), TEVA: 63.01 (-1.15)
UniQure Deal Confirms Red-Hot Interest In Advanced Therapies
EP Vantage - at Seeking Alpha - Tue Apr 07, 3:42PM CDT
If there is any sign that pharma is beating the bushes to flush out promising advanced therapies, it is that Bristol-Myers Squibb (NYSE: BMY ) has shelled out $50m to license a preclinical gene therapy project that UniQure (NASDAQ: QURE ) ...
BLUE: 136.49 (+1.22), CLDN: 13.59 (-2.77), BMY: 66.60 (-0.21)
Another IPO Filed In Hot Cancer Immunotherapy Field
at Investor's Business Daily - Tue Apr 07, 12:55PM CDT
Adaptimmune Therapeutics has filed for an initial public offering, adding another company to one of the hottest sectors in the biotech field. U.K.-based Adaptimmune Therapeutics plans to raise up to $150 million and list on the Nasdaq under the...
BLUE: 136.49 (+1.22), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), AMGN: 169.10 (+0.64), JUNO: 55.72 (-0.68)
Why uniQure N.V. Stock Skyrocketed Today
George Budwell, The Motley Fool - Motley Fool - Mon Apr 06, 9:35AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of the Dutch gene-therapy company uniQure ...
BLUE: 136.49 (+1.22), JNJ: 100.43 (+0.13), QURE: 26.15 (-1.44), PFE: 34.93 (+0.04), CLDN: 13.59 (-2.77), BMY: 66.60 (-0.21), NVS: 103.45 (-0.62)
3 Events That Could Sink the Biotech Sector This Year
Brian Orelli, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Sun Apr 05, 8:06AM CDT
The biotech sector has been hot over the last few years, which naturally leads to talk of a biotech bubble. We asked our healthcare experts for potential events that might pop that bubble -- or at least let a little air out. While we're certainly...
BLUE: 136.49 (+1.22), IMS: 27.73 (+0.04), ESRX: 86.12 (+0.02), GILD: 104.18 (-1.02), CLDN: 13.59 (-2.77), ABBV: 64.52 (+0.91)
Celladon: The Next Breakthrough In Cardiovascular Gene Therapy?
DoconStocks - at Seeking Alpha - Tue Mar 31, 7:48AM CDT
BLUE: 136.49 (+1.22), ONCE: 64.79 (-0.25), CLDN: 13.59 (-2.77)
Intrexon and Merck Serono team up in cancer immunotherapy
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 8:05AM CDT
BLUE: 136.49 (+1.22), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), XON: 44.53 (+0.36), JUNO: 55.72 (-0.68)
Today's Review on Biotech Equities -- Biocept, Biogen Idec, Kite Pharma, Organovo Holdings, and Bluebird Bio
PR Newswire - Mon Mar 30, 7:55AM CDT
Editor Note: For more information about this release, please scroll to bottom.
BLUE: 136.49 (+1.22), BIIB: 423.57 (+1.46), KITE: 57.56 (-1.43), ONVO: 5.14 (+0.67), BIOC: 3.15 (+0.02)
1 Clinical-Stage Biotech Stock That Could Make You Into a Millionaire
George Budwell, The Motley Fool - Motley Fool - Sun Mar 29, 7:06AM CDT
Biotech stocks have the ability to absolutely crush it in short order, turning even small investments into respectable sums of money. Investors that caught lightning in a bottle with Acadia Pharmaceuticals prior to the company releasing pivotal...
BLUE: 136.49 (+1.22), ACAD: 38.55 (-0.20), CLDN: 13.59 (-2.77)
Could These Experimental Drugs Eclipse Harvoni's Historic Launch?
Keith Speights, Brian Orelli, and Todd Campbell, The Motley Fool - Motley Fool - Sat Mar 28, 7:02AM CDT
Relatively few drugs attain the esteemed blockbuster status of $1 billion in annual sales. For those that do, many of them take several years to reach that mark. Gilead Sciences , however, raised the bar with the launch of hepatitis C drug Harvoni....
BLUE: 136.49 (+1.22), BIIB: 423.57 (+1.46), ESRX: 86.12 (+0.02), GILD: 104.18 (-1.02), PFE: 34.93 (+0.04), AMGN: 169.10 (+0.64)
Celladon Heart-Failure Study Looms Large as Next Big Test for Gene Therapy
at The Street - Wed Mar 25, 9:06AM CDT
In April, Celladon is expecting results from a mid-stage study of a gene therapy aiming to improve the pumping ability of the heart in patients with advanced heart failure.
BLUE: 136.49 (+1.22), ONCE: 64.79 (-0.25), CLDN: 13.59 (-2.77)
Mast Therapeutics: Investment Opportunity As Phase III Ongoing
Capital Screen - at Seeking Alpha - Fri Mar 20, 10:17AM CDT
BLUE: 136.49 (+1.22), MSTX: 0.50 (+0.01), GLYC: 8.84 (-0.04)
How ARM's Edward Lanphier Is Fighting For Cell Therapy Cures That Save Patients And Portfolios
Life Sciences Report - Seeking Alpha - Fri Mar 20, 6:52AM CDT
Stem cell, gene therapy and genetically modified cell therapy companies have begun to attract serious capital from investors who understand biotechnology and have the wherewithal to move products into the clinic and into the market. But battles still...
BLUE: 136.49 (+1.22), QURE: 26.15 (-1.44), SGMO: 14.37 (-0.03), JUNO: 55.72 (-0.68), ATHX: 1.34 (+0.01), NVS: 103.45 (-0.62)
Juno Therapeutics Comments On Cancer Cure Lifts Group
at Investor's Business Daily - Thu Mar 19, 1:36PM CDT
Enthusiasm about potential cancer cures sent shares of Juno Therapeutics (JUNO) and its peers flying Thursday, though Juno's fourth-quarter earnings late Wednesday missed Wall Street estimates by a lot. "Within the next 12 months, we expect to have...
BLUE: 136.49 (+1.22), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), AMGN: 169.10 (+0.64), JUNO: 55.72 (-0.68), NVS: 103.45 (-0.62)
CAR-T cancer therapy stocks head north
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 12:29PM CDT
BLUE: 136.49 (+1.22), ZIOP: 10.88 (+0.03), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), CNDO: 4.09 (-0.09), CLLS: 31.30 (-0.91), JUNO: 55.72 (-0.68)
CJS Global Complete Janitorial Solutions Expands Services to Central Florida, Signing on Many High-Profile Companies
PR Newswire - Thu Mar 19, 7:45AM CDT
CJS (Complete Janitorial Solutions) Global, founded by successful business owner Taylor Smith in Fort Lauderdale in March 2012, has recently expanded its services to the Orlando market. CJS is pleased to now provide services for renowned franchises in the Orlando, Tampa, Sarasota, Fort Myers, Daytona and Jacksonville areas, including Seasons 52, Dewey's Indoor Golf & Sports Grill, Roy's Hawaiian, Miller's Ale House Restaurant, Blue Martini, Kings Bowling Orlando, Taverna Opa, BRIO Tuscan Grille, Chili's and Bahama Breeze.
BLUE: 136.49 (+1.22)
Cellectis on deck for what should be a very strong IPO
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 9:42AM CDT
BLUE: 136.49 (+1.22), BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), PFE: 34.93 (+0.04), CLLS: 31.30 (-0.91), JUNO: 55.72 (-0.68)
bluebird bio to Present at Alliance for Regenerative Medicine's 3rd Annual Regen Med Investor Day
Business Wire - Wed Mar 18, 6:00AM CDT
bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the Alliance for Regenerative Medicine's 3rd Annual Regen Med Investor Day on Wednesday, March 25, 2015 at 4:20 p.m. ET at the Metropolitan Club in New York City. bluebird bio will also participate in a panel titled, "Adoptive T-Cell Therapies: Considering Key Upcoming Clinical & Commercial Milestones" at 3:10 p.m. ET.
BLUE: 136.49 (+1.22)
